One dose of protein-targeting CAR-T cells shrinks solid tumors in preclinical tests

Дата публикации: 05-10-2026 17:00:11

CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers. However, their use in solid tumors such as liver, breast or lung cancer has so far been significantly more difficult. This is due, among other things, to the lack of suitable target structures on the cancer cells. Cancer immunotherapies typically target features that are characteristic of a tumor and that, in some cases, directly drive its growth. However, such mutations are not always present or cannot be exploited therapeutically.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy	0	6.96	28-09-2026
2	Scientists reprogram immune cells inside the body to fight cancer	0	10.28	07-10-2026
3	Targeted nanoparticles reduce tumor scarring and enable immunotherapy response in mice	0	7.8	25-09-2026
4	Drug Used to Treat Asthma and Allergies May Also Help Fight Aggressive Cancers	0	5.67	24-05-2026
5	Experimental cancer treatment disrupts cell communication to suppress tumor growth in animal tests	0	7.23	07-10-2026
6	'Plug-and-play' CAR T technology adapts as cancer changes	0	8.18	22-09-2026
7	Stanford scientists turn a cancer driver into a kill switch	0	15.26	08-10-2026
8	Cancer biologists bring in the B-cell reinforcements for immunotherapy	0	8.93	17-09-2026
9	New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?	0	8.36	30-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 8.74. Источник: medicalxpress.com.